A phase II study of Docetaxel with Bevacizumab for EGFR mutation negative previously treated non-squamous non-small cell lung cancer

Phase 2

• Conditions: on-Squamous Non-Small Cell Lung Cancer

• Registration Number: JPRN-UMIN000006532
• Lead Sponsor: ihon University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-14
• Study Completion: 2014-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. EGFR mutation status positive 2. CNS metastasis 3. History or complication of hemoptysis with 2.5mL per time or more. Continuouis bloody phlegm more than 1 week. History or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. 4. Tendency to hemorrhages 5. continuous medication with anticoagulant drug(including Aspirin over 325mg/day) for Thrombus treatment 6. Invasion to major vessel or cavitations of tumor 7. Planning of concurrent thoracic radiotherapy (excluding if radiation field does not cover the chest 8. Pericardial effusion requiring drainage 9. Superior vena cava syndrome 10. Uncontrollable peptic ulcer 11. History of GI perforation 12. Uncontrollable hypertension 13. Symptomatic congestive heart failure, Unstable angina, arrhythmia requiring treatment 14. Severe myelosuppression 15. Severe infection 16. Severe psychological illness 17. Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 18. With a history of drug sensitivity for Docetaxcel or Bevacizumab. 19. In pregnancy, during breast feeding, or possibility of pregnancy. 20. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression Free Survival

Secondary Outcome Measures

Name	Time	Method
Response Rate Disease Control Rate Overall Survival Maximum tumor volume change Safety Profile